Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: Insights into liver disorders and liver cancer

Lin, Guozhen; Miao, Peng

doi:10.1016/j.ejphar.2020.173616

Cited by 10 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In GAN-fed mice, we observed an increase in HDL-c levels, which may be attributed to the consumption of palm oil, a saturated fat that has been shown to elevate HDL-c ( 32 ). However, in the OCA group, there was a significant reduction in HDL-c, which has already been described as a known side effect ( 33 ).…”

Section: Discussionmentioning

confidence: 65%

Healthy diet intervention reverses the progression of NASH through gut microbiota modulation

Panyod,

Wu,

et al. 2024

Microbiol Spectr

View full text Add to dashboard Cite

Diet and gut microbiota impact the progression of non-alcoholic steatohepatitis (NASH). An unhealthy diet, rich in fat and sugar, promotes gut microbiota dysbiosis, leading to the translocation of lipopolysaccharides (LPS) and other harmful pathogen-associated molecular patterns to the liver, triggering hepatic inflammation and aggravating NASH. Currently, there are no approved pharmacological treatments for NASH, although novel drugs, such as obeticholic acid (OCA), have demonstrated beneficial effects. Healthy dietary modifications have been proposed to prevent and treat NASH. However, the therapeutic effect of the combined implementation of a healthy dietary intervention with pharmaceutical agents or dietary supplements for NASH treatment and how it interplays with the gut microbiota and associated pathways remains poorly understood. This study aims to investigate the therapeutic efficacy of a healthy dietary modification, either alone or in combination with a dietary supplement [ginger essential oil (GEO)] or drug (OCA), in a Gubra-Amylin diet-induced NASH mouse model. NASH was induced for 12 weeks, after which the interventions were administered for a subsequent 3-week period. Our findings revealed that healthy dietary intervention primarily restores obesity, lipidemia, and NASH. In contrast, GEO and OCA have additional benefits by suppressing pro-inflammatory cytokines by partially modulating the NLRP3/ASC/caspase-1 pathways. Moreover, healthy dietary intervention restores gut microbiota composition and function from dysbiosis, while GEO and OCA partially mediate the gut-derived LPS/toll-like receptor 4/nuclear factor kappa B pathway. Therefore, adherence to healthy dietary patterns plays a primary role in NASH reversion, and additional supplementation of GEO or OCA could offer extra benefits in suppressing hepatic inflammation and preventing disease progression. IMPORTANCE The link between gut microbiota and diet is crucial in the development of non-alcoholic steatohepatitis (NASH). This study underscores the essential role of a healthy diet in preventing and treating NASH by reversing obesity, lipidemia, and gut microbiota dysbiosis. Moreover, the supplementation of functional food or drug to the diet can provide additional advantages by inhibiting hepatic inflammation through the modulation of the hepatic inflammasome signaling pathway and partially mediating the gut microbiota and lipopolysaccharide signaling pathway. This study highlights the importance of adopting healthy dietary habits in treating NASH and proposes that supplementing with ginger essential oil or obeticholic acid may offer additional benefits. Nonetheless, further clinical studies are necessary to validate these findings.

show abstract

Section: Discussionmentioning

confidence: 65%

Healthy diet intervention reverses the progression of NASH through gut microbiota modulation

Panyod,

Wu,

et al. 2024

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Additionally, OCA increases total cholesterol and LDL cholesterol and decreases HDL cholesterol by altering LDL and HDL particles concentrations. 188,189 The unfavorable increase in circulating cholesterol results from the inhibition of conversion of cholesterol to bile acids by OCA and consequently from cholesterols' increased availability. The approval of OCA for the treatment of NASH is awaited in the near future.…”

Section: Farnesoid X Receptor Agonists (Obeticholic Acid)mentioning

confidence: 99%

“…Although OCA seems to have effects on steatosis regression, they appear to be relatively small and not significant. Additionally, OCA increases total cholesterol and LDL cholesterol and decreases HDL cholesterol by altering LDL and HDL particles concentrations 188,189 . The unfavorable increase in circulating cholesterol results from the inhibition of conversion of cholesterol to bile acids by OCA and consequently from cholesterols' increased availability.…”

Section: Pharmacologic and Non‐pharmacologic Interventions For Reduci...mentioning

confidence: 99%

Liver fat as risk factor of hepatic and cardiometabolic diseases

et al. 2023

View full text Add to dashboard Cite

SummaryNon‐alcoholic fatty liver disease (NAFLD) is a disorder characterized by excessive accumulation of fat in the liver that can progress to liver inflammation (non‐alcoholic steatohepatitis [NASH]), liver fibrosis, and cirrhosis. Although most efforts for drug development are focusing on the treatment of the latest stages of NAFLD, where significant fibrosis and NASH are present, findings from studies suggest that the amount of liver fat may be an important independent risk factor and/or predictor of development and progression of NAFLD and metabolic diseases. In this review, we first describe the current tools available for quantification of liver fat in humans and then present the clinical and pathophysiological evidence that link liver fat with NAFLD progression as well as with cardiometabolic diseases. Finally, we discuss current pharmacological and non‐pharmacological approaches to reduce liver fat and present open questions that have to be addressed in future studies.

show abstract

Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway

Zhang

Feng²,

et al. 2022

Arch Toxicol

View full text Add to dashboard Cite

Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: Insights into liver disorders and liver cancer

Cited by 10 publications

References 38 publications

Healthy diet intervention reverses the progression of NASH through gut microbiota modulation

Healthy diet intervention reverses the progression of NASH through gut microbiota modulation

Liver fat as risk factor of hepatic and cardiometabolic diseases

Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway

Contact Info

Product

Resources

About